Precipio Inc. (TGK)
XMUN 
Summary
Precipio Stock Up Following Solid Q3 Earnings and Improved Cash Flow
PRPO reports strong third-quarter 2025 results with higher revenue, positive cash flow and improved margins in core divisions.
Precipio, Inc. (PRPO) Q3 2025 Earnings Call Prepared Remarks Transcript
Precipio, Inc. ( PRPO ) Q3 2025 Earnings Call November 17, 2025 5:00 PM EST Company Participants Ilan Danieli - Founder, President, CEO & Director Presentation Operator Welcome to the Precipio Third Quarter 2025 Shareholder Update Conference Call. [Operator Instructions] Please note that the conference is being recorded.
Precipio, Inc. (PRPO) Q2 2025 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q2 2025 Earnings Conference Call August 14, 2025 5:00 PM ET Company Participants Ilan Danieli - Founder, President, CEO & Director Operator Welcome to the Precipio Q2 2025 Shareholder Update Conference Call. [Operator Instructions] Please note that this conference is being recorded.
Precipio Inc. (TGK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Precipio Inc. ever had a stock split?
Precipio Inc. Profile
| Professional Services Industry | Industrials Sector | Ilan Danieli CEO | XMUN Exchange | US74019L6020 ISIN |
| US Country | 54 Employees | - Last Dividend | 22 Sep 2023 Last Split | 18 Jul 2000 IPO Date |
Overview
Precipio, Inc. is a healthcare solutions provider that specializes in diagnostic products, reagents, and services, primarily within the United States. This company focuses on delivering diagnostic testing services for blood cancers, utilizing innovative technology to facilitate accurate results. Their product portfolio includes proprietary cell culture media, genetic diagnostic panels, and COVID-19 antibody tests. Precipio, Inc. is headquartered in New Haven, Connecticut, and caters to bio-pharma customers with their ICE- technology kits, alongside their direct diagnostic services.
Products and Services
- IV-Cell:
A proprietary cell culture media developed by Precipio, Inc., IV-Cell is designed to enable the simultaneous culturing of four different hematopoietic cell lineages. This innovation supports more comprehensive and efficient blood cancer testing, facilitating the cultivation of various cells for better diagnostic accuracy.
- HemeScreen:
A suite of robust genetic diagnostic panels, HemeScreen is tailored to streamline the detection and analysis of genetic markers associated with blood cancers. These panels offer healthcare providers critical insights required for precise diagnosis and tailored treatment strategies, utilizing advanced genetic screening techniques.
- COVID-19 Antibody Tests:
In response to the global pandemic, Precipio, Inc. has expanded its diagnostic offerings to include COVID-19 antibody tests. These tests are designed to identify the presence of antibodies against the virus, indicating previous infection and possibly the extent of an individual’s immune response to COVID-19, hence contributing valuable data for public health and individual care decisions.
- ICE- Technology Kits:
Targeting bio-pharma customers, these technology kits leverage Precipio’s innovative ICE- technology, designed to enhance the efficacy and efficiency of pharmaceutical research and development. By providing cutting-edge tools for bio-pharmaceutical companies, Precipio, Inc. aids in the acceleration of research processes, potentially speeding up the time-to-market for new therapies.
Contact Information
